NCT00879411已完成不适用
24h BP Under Micardis in Daily Practice
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 670
- 主要终点
- Efficacy (Change of Systolic Blood Pressure)
研究概览
简要总结
Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
arterial hypertension
干预措施: Micardis (Drug)
结局指标
主要结局
Efficacy (Change of Systolic Blood Pressure)
时间窗: baseline to 8 weeks
Change from baseline in 24h systolic blood pressure (BP) at week 8
Efficacy (Change of Diastolic Blood Pressure)
时间窗: baseline to 8 weeks
Change from baseline in 24h diastolic blood pressure (BP) at week 8
次要结局
- Overall Tolerability Scale(8 weeks)
研究者
相似试验
已完成
不适用
Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With HypertensionHypertensionNCT02242383Boehringer Ingelheim13,248
已完成
不适用
Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)HypertensionNCT02262637Boehringer Ingelheim4,814
已完成
不适用
Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood PressureHypertensionNCT02242864Boehringer Ingelheim1,527
已完成
不适用
Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)HypertensionNCT02243566Boehringer Ingelheim2,707
已完成
不适用
Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes MellitusHypertensionNCT02242825Boehringer Ingelheim8,148